Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary treatment in nasopharynx cancers is radiotherapy (RT) or chemoradiotherapy (CRT) depending on the stage of the tumor. According to the guidelines, the dose of radiotherapy for primary tumors varies between 66-70 Gy. In consideration of modern radiotherapy techniques like IMRT with systemic chemotherapy for nasopharyngeal cancer, loco-regional control has been perfect. However, the rate of late complications from treatment, many of which are irreversible, is still high. Radiation-related optic neuropathy is the late complication that optic nerves might be affected during the radiotherapy due to the close location of the nasopharynx. Incidence of this is 8.7-9% in head and neck cancer and is observed between 2-9 years after RT. Painless, irreversible, and progressive vision loss usually occurs, and the pallor of optic disc margins, retinal vein dilatation, bleeding, and neovascularization are in the ophthalmic examination. The risk of optic neuropathy increases when the tumor is in close contact with optic nerves, radiation dose, concurrent chemotherapy used, history of diabetes or hypertension.
The aim of our study is to prospectively evaluate optic neuropathy in nasopharynx cancer patients treated in our clinic.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient with nasopharyngeal carcinoma that histopathologically confirmed Age >18 Radiotherapy or chemoradiotherapy applied to the patient in our clinic No recurrence or metastasis during follow-up Optic evaluation Evaluation with MRI or CT during follow-up
Exclusion criteria
Cranial RT No histopathological verification Age< 18 There were locoregional recurrence or metastasis
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Meltem Dağdelen, MD; Ceren Barlas, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal